✨ Onyx Summary Legend Biotech Corporation was named Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its long-term investment and expansion of CAR-T cell therapy manufacturing in Ghent, Belgium. The award reflects a €165 million joint investment with Johnson & Johnson that has scaled
✨ Onyx Summary Rocket Pharmaceuticals announced that CEO Dr. Gaurav Shah will participate in a fireside chat and investor meetings at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance provides a platform to engage investors on Rocket’s late-stage gene therapy pipeline and strategic priorities as
✨ Onyx Summary Lexicon Pharmaceuticals announced that company management will participate in fireside chats at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025, with live and replay access available through the company’s investor website. THE WOODLANDS,
✨ Onyx Summary enGene Holdings Inc. announced that Chief Strategy and Operations Officer Alex Nichols, Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a webcast available via the company’s investor website. BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”
✨ Onyx Summary Foghorn Therapeutics announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025, with a webcast available via the company’s investor website. CAMBRIDGE, Mass., Nov. 25, 2025 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering
✨ Onyx Summary Belite Bio assigned its rights and obligations under its exclusive Columbia University license from its Hong Kong subsidiary to its Swiss subsidiary as part of a capital contribution. The move positions the company for potential future sublicensing or collaborations while leaving current operations unchanged. SAN DIEGO, November 24,
✨ Onyx Summary Ocugen announced that CEO and co-founder Dr. Shankar Musunuri will present at NobleCon21 on December 3, 2025, where he plans to outline progress toward the company’s goal of “three BLAs in three years” and discuss 2026 catalysts across its modifier gene therapy platform for blindness diseases.
✨ Onyx Summary Keros Therapeutics, Inc. announced the final results of its cash tender offer, repurchasing 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender, which applied a final proration factor of roughly 62.3%, concludes
✨ Onyx Summary Perspective Therapeutics announced that members of its senior leadership team will participate in fireside chats and investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. SEATTLE, Nov. 20, 2025 – November 20, 2025
✨ Onyx Summary Avidity Biosciences launched an FDA-authorized Managed Access Program in the United States to provide investigational delpacibart zotadirsen to eligible patients with Duchenne muscular dystrophy amenable to exon 44 skipping, addressing a population with no approved exon-skipping therapies. The program aligns with Avidity’s planned 2026 BLA
✨ Onyx Summary Keros Therapeutics, Inc. announced preliminary results of its cash tender offer, expecting to repurchase 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender concludes Keros’ previously announced $375 million capital return program, materially
✨ Onyx Summary Alzheon, Inc. announced it will present new long-term efficacy, safety, and quantitative systems pharmacology data for its oral Alzheimer’s therapy valiltramiprosate (ALZ-801) at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The presentations will highlight three-year Phase 2 extension
Jefferies Global Healthcare Conference in London Date: November 17-20, 2025 To view the webcast, please click here.
✨ Onyx Summary A new Harris Poll survey commissioned by ImmunityBio finds that most U.S. patients with non-muscle invasive bladder cancer receive limited discussion of treatment options despite heavy reliance on healthcare providers for guidance, and many seek alternatives to chemotherapy, including immunotherapy. The results underscore a communication gap
✨ Onyx Summary Legend Biotech opened a new 31,000-square-foot R&D facility in Philadelphia to support expansion of its next-generation cell therapy pipeline, adding approximately 55 research staff and strengthening its U.S. footprint. The site enhances the company’s innovation capabilities alongside existing New Jersey
✨ Onyx Summary enGene priced its underwritten public offering of 12.6 million common shares and 2.7 million pre-funded warrants, raising approximately $130 million in gross proceeds, with a 30-day overallotment option available to underwriters. The financing, conducted under the company’s effective shelf registration, is expected to
